Background Gemtuzumab ozogamicin was the first example of antibody-directed
chemotherapy in cancer, and was developed for acute myeloid leukaemia. However …

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-drug conjugate for the treatment of
acute myeloid leukemia (AML). Although GO shows a narrow therapeutic window in early …

In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …

In the past three decades, improvements in the treatment of acute myeloid leukemia (AML)
have increased survival in patients younger than 55 years without significant survival impact …

The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony‐stimulating
factor (FLAG‐Ida) is widely used in relapsed/refractory acute myeloid leukaemia (AML). We …

Due to the high rate of relapse in younger patients and the overall poor outcome in older
patients, novel therapies are needed for the treatment of acute myeloid leukemia (AML) …

Gemtuzumab ozogamicin (CMA-676, Mylotarg®), an antibody-targeted chemotherapy
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …

Relapsed acute myeloid leukemia (AML) carries a poor prognosis. Treatment options are
limited, and their toxicities are substantial. There is an urgent need for novel therapies that …

Gemtuzumab ozogamicin is currently approved to treat CD33‐positive acute myeloid
leukemia (AML) in first relapse in patients older than age 60 years. The objective of this …

The purpose of this study was to characterize the pharmacokinetics of gemtuzumab
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …